Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to evaluate the role of nutritional Vitamin D deficiency as a potential contributor to the morbidity witnessed in patients with end-stage renal disease

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Kansas
• Treatments: Cholecalciferol; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• End-stage renal disease undergoing maintenance hemodialysis at KUMC outpatient hemodialysis unit

• Dialysis vintage of at least 6 months duration

• Nutritional vitamin D deficiency, defined as 25(OH)D <25 ng/ml

• Age 21 to 88 years

Exclusion Criteria:

• Active infection

• Recent hospitalization for acute illness (within last 1 month)

• Refusal to study participation

• Poorly controlled secondary hyperparathyroidism (iPTH>500)

• History of chronic inflammatory disease process, such as inflammatory bowel, rheumatoid arthritis, lupus, etc.

• Cinacalcet therapy

• Previous allergy to ergocalciferol

• History of parathyroidectomy

• Current treatment with immunosuppressant medications

• Noncompliance with prescribed hemodialysis regimen (i.e. skipping treatments, ending sessions early)

• Functional renal transplant within the last five years